GU Cancers 2023 | Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, discusses an investigation into the association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Retrospective analyses have explored the timing of administration of immunotherapy, which has been shown in lung cancer and melanoma to have an impact on patient outcomes. Dr Dizman provides an overview of an investigation into the timing of immunotherapy administration in metastatic renal cell carcinoma with nivolumab plus ipilimumab and nivolumab monotherapy. Patients who received less than 25% of infusions after 4:30 pm were assigned to the early time of infusion (TOI) sub-cohort while patients who received ≥ 25% of infusions after 4:30 pm were assigned to the late TOI sub-cohort. Objective response rate (ORR, per RECIST 1.1), time to treatment failure (TTF, defined as time from the date of first ICI infusion to time of treatment discontinuation), and overall survival (OS) were compared across the two groups. 29.6% of patients responded to treatment with late TOI and 37% of patients responded with early TOI. Additionally, numerical differences were seen in progression-free survival (PFS) and overall-survival (OS). TTF was 9.5 months in the early TOI cohort versus 4.6 in the late TOI cohort. Statistical significance wasn’t observed, although numerical differences were notable. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.